
    
      This Phase III study will assess the efficacy and safety of durvalumab in combination with
      platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab
      with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial
      cancer.

      Target patient population: Adult female patients with histologically confirmed diagnosis of
      epithelial endometrial carcinoma (excluding sarcomas): newly diagnosed Stage III, newly
      diagnosed Stage IV, or recurrent endometrial cancer
    
  